New York, February 23, 2026, 16:52 (ET) — Trading after the bell.
- Vanda shares jumped roughly 41% after traders piled in, betting on FDA approval for its new antipsychotic, Bysanti.
- According to a regulatory filing, the approval came through, with a U.S. rollout set for the third quarter.
- Analysts reacted positively to the catalyst, though some raised questions about how demand will stack up against Vanda’s older drug Fanapt.
Vanda Pharmaceuticals Inc (VNDA.O) surged 41% on Monday, after a regulatory filing revealed the U.S. Food and Drug Administration gave the green light to its latest antipsychotic drug, Bysanti. Shares finished the session at $8.15, up $2.39. Trading volume spiked to about 47.6 million shares—roughly 26 times the usual daily number, market data showed. 1
The magnitude of the jump is key—Vanda spent years stuck in small-cap land, and an FDA decision can flip the story in a hurry. With a second branded psychiatry drug, there’s a fresh launch on deck to market, rather than just another pipeline bullet point.
Vanda steps into a crowded corner of the market here. Antipsychotics already fill the shelves, payers drag their feet, and doctors usually don’t budge from familiar scripts unless a new option gives them an obvious reason.
Vanda announced in its press release that Bysanti (milsaperidone) received approval for use in adults with schizophrenia and for treating acute manic or mixed episodes associated with bipolar I disorder. CEO Mihael H. Polymeropoulos described the drug as “a reliable new treatment grounded in extensive clinical heritage.” U.S. commercial launch is targeted for the third quarter, with marketing exclusivity protected by data exclusivity and several patents—the last of which runs through 2044. The company added it aims to wrap up a depression study by year-end. 2
Bysanti, which “rapidly interconverts” to iloperidone, targets brain receptors involved in dopamine and serotonin signalling, according to post-approval drug info. The label features the standard boxed warning for the class—higher risk of death in elderly patients with dementia-related psychosis. 3
Some remain unconvinced by the commercial pitch. Jefferies analyst Andrew Tsai, before the approval, flagged a key point: Bysanti is “essentially more or less the same drug” as Fanapt. That brings up the issue—why would patients pick Bysanti once Fanapt goes off-patent, likely around late 2027 or 2028? Tsai’s estimates show Bysanti sales hitting about $200 million by 2033. 4
On the flip side, H.C. Wainwright wasted little time bumping up its price target for Vanda, lifting it to $24 from $22 while sticking with a buy rating after the FDA news, a note showed Monday. 5
Vanda described the FDA nod as another notch in a string of regulatory successes, touting Bysanti as its second fresh drug approval in under two months—Nereus was cleared in December. 6
But at this point, the FDA news is only part of the story. What really matters: execution. That means access, how it’s priced, and if doctors actually view it as different enough to prescribe. Any hiccup on launch timing, delays in coverage, or a tougher blow from generics down the line—all of that could make Monday’s rally look overdone.
Eyes shift to Vanda as it irons out its commercialization plan before the third-quarter launch. Another milestone: results from its depression study, expected this year, which could finally attach real figures to the approval.
